Vijaya Diagnostic Centre
- Market Cap
- ₹16,194 Cr
- P/E
- 79.45
Key Fundamentals
SmallcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 20.50%
- Debt to Equity
- 0.48
- EPS (TTM)
- ₹19.79
- Book Value
- ₹102.62
- Market Cap
- ₹16,194 Cr
- P/E (TTM)
- 79.45
- P/B
- 15.32
- ROE
- 18.90%
- Dividend Yield
- 0.13%
- EBITDA
- ₹358 Cr
- 52W High
- ₹1,593.60
- 52W Low
- ₹848.00
- Day Range
- ₹1,500.30 – ₹1,587.00
- Volume
- 5,38,498
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| 2,006.00 | 57.48 | 33,670 | 12.27 | 0.51% | 22.30% | 28.00% | 3,034 | 587 | |
| 1,572.30 | 79.45 | 16,194 | 15.32 | 0.13% | 18.90% | 20.50% | 911 | 203 | |
| 566.00 | 52.31 | 11,738 | 7.15 | 0.18% | 13.60% | 17.80% | 1,778 | 225 | |
| 528.45 | 58.33 | 8,411 | 15.21 | 2.78% | 28.40% | 35.40% | 930 | 143 | |
| 655.80 | 51.39 | 6,595 | 5.55 | 0.00% | 8.83% | 15.30% | 1,110 | 128 | |
| 519.05 | 16.67 | 1,684 | 1.60 | 0.39% | 10.90% | 12.70% | 783 | 100 | |
| 311.50 | 38.79 | 1,622 | 5.88 | 0.14% | 14.20% | 17.30% | 346 | 41 | |
| Median 7 companies | 566.00 | 52.31 | 8,411 | 7.15 | 0.18% | 14.20% | 17.80% | 930 | 143 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 72
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 17
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 68
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 42
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 58
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 43
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
1- Stock is trading at 15.3 times its book value
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 4 | 12 |
| Oscillators | Bearish | 3 | 4 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 65.19
- Neutral
- MACD (12,26,9)
- 21.05
- Bullish
- SMA (50)
- 1,458.30
- Bullish
- SMA (200)
- 1,269.20
- Bullish
As of
Analyst Rating
7 of 8 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | +16.64% |
|---|---|
| 3Y | +21.04% |
| 1Y | +19.53% |
| TTM | +24.32% |
Net profit
| 5Y | +15.27% |
|---|---|
| 3Y | +26.73% |
| 1Y | +20.14% |
| TTM | +33.55% |
Operating cash flow
| 5Y | +15.83% |
|---|---|
| 3Y | +17.99% |
| 1Y | +20.98% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −2.63 pp |
|---|---|
| 3Y | +1.75 pp |
| 1Y | +1.31 pp |
| TTM | +3.41 pp |
Revenue by year
| Mar 2018 | ₹251 Cr |
|---|---|
| Mar 2019 | ₹293 Cr |
| Mar 2020 | ₹339 Cr |
| Mar 2021 | ₹377 Cr |
| Mar 2022 | ₹462 Cr |
| Mar 2023 | ₹459 Cr |
| Mar 2024 | ₹548 Cr |
| Mar 2025 | ₹681 Cr |
| Mar 2026 | ₹814 Cr |
Net profit by year
| Mar 2018 | ₹35.00 Cr |
|---|---|
| Mar 2019 | ₹46.00 Cr |
| Mar 2020 | ₹63.00 Cr |
| Mar 2021 | ₹85.00 Cr |
| Mar 2022 | ₹111 Cr |
| Mar 2023 | ₹85.00 Cr |
| Mar 2024 | ₹120 Cr |
| Mar 2025 | ₹144 Cr |
| Mar 2026 | ₹173 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Vijaya Diagnostic Centre Ltd trades at ₹1,510.6 as of 2026-11-19 with a market cap of ₹15,558.83 crore, a PE of 76.33x and ROE of 18.07%. The stock has delivered a 1-year CAGR of 49% and compounded profit growth of 33% TTM, but trades at 14.71x book value, reflecting a rich valuation relative to its earnings base.
- Strong revenue momentum with TTM compounded sales growth of 24% and a 3-year compounded sales CAGR of 21%, indicating consistent top-line expansion in the diagnostics space
- TTM compounded profit growth of 33% outpaces sales growth of 24%, suggesting improving operating leverage and margin expansion
- Stock has delivered a 1-year CAGR of 49%, significantly outperforming broader market indices and reflecting strong investor confidence
- Consistent ROE of 19% over the last 1, 3 and 5-year periods demonstrates stable and efficient capital deployment
- ROCE of 19.22% as of 2026-11-19 indicates the business generates healthy returns on total capital employed, including debt
- Conservative balance sheet with a debt-to-equity ratio of just 0.44, providing financial flexibility for future expansion without excessive leverage
- 3-year stock CAGR of 34% and 5-year stock CAGR of 21% show sustained long-term wealth creation for shareholders
- 5-year compounded profit growth of 15% and 5-year compounded sales growth of 17% demonstrate the company has maintained a durable growth trajectory over a multi-year period
- PE ratio of 76.33x as of 2026-11-19 is extremely elevated, requiring sustained high earnings growth over many years to justify the current price
- Dividend yield of just 0.13% offers negligible income return to shareholders, meaning returns depend almost entirely on capital appreciation
- At ₹1,510.6 the stock trades near its 52-week high of ₹1,593.6, just 5.2% below the peak, raising the risk of mean reversion after a sharp rally from the 52-week low of ₹848
- The gap between 5-year compounded profit growth of 15% and the current PE of 76.33x implies a PEG ratio well above 1, suggesting the valuation may be running ahead of the longer-term earnings growth trajectory
- Market cap of ₹15,558.83 crore against TTM EPS of ₹19.79 means any deceleration in the 33% TTM profit growth rate could trigger a sharp de-rating of the multiple
- ROE of 18.07% is respectable but not exceptionally high for a capital-light diagnostics business trading at 14.71x price-to-book, raising questions about whether such a premium is warranted
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Vijaya Diagnostic is delivering strong growth with Q2FY27 profit up 35% and revenue up 27.4% YoY, reflecting solid operational expansion in the diagnostics space. No material headwinds surfaced in the recent news cycle. The upcoming investor meet signals continued engagement with institutional investors. The growth trajectory looks healthy, and sustained revenue expansion will be key to watch in coming quarters.
- Q2FY27 PAT surges 35% YoY Nov 03
Standalone net profit rose 35% YoY to ₹579.2 lakh in Q2FY27. Revenue grew 27.4% YoY to ₹242 crore, driven by operational expansion.
- Investor meet in Chennai Nov 18
Vijaya Diagnostic will hold an analyst and institutional investor meeting in Chennai on December 11, 2026.
- New Company Secretary appointed Nov 03
Rahul Jain appointed as Company Secretary and Compliance Officer effective November 3, 2026, following Board approval under SEBI regulations.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 | 231 | 255 |
| Expenses | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 | 132 | 143 |
| Operating Profit | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 | 99 | 113 |
| OPM % | 41% | 39% | 41% | 39% | 42% | 40% | 40% | 39% | 41% | 42% | 44% | 43% | 44% |
| Other Income | 7 | 5.11 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 | 9 | 4.95 |
| Interest | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 | 11 | 11.38 |
| Depreciation | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 | 25 | 26.9 |
| PBT | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 | 71 | 79.42 |
| Tax % | 25% | 25% | 23% | 25% | 26% | 24% | 26% | 26% | 25% | 26% | 25% | 25% | 25% |
| Net Profit | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 | 53 | 59.47 |
| EPS (₹) | 3.26 | 2.53 | 3.27 | 3.06 | 4.10 | 3.43 | 3.40 | 3.76 | 4.21 | 4.20 | 4.66 | 5.16 | 5.77 |
| YoY Sales growth | 15 | 17 | 28 | 29 | 32 | 27 | 12 | 20 | 10 | 21 | 27 | 23 | 27 |
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 251 | 293 | 339 | 377 | 462 | 459 | 548 | 681 | 814 | 911 |
| Expenses | 171 | 184 | 206 | 211 | 259 | 277 | 327 | 408 | 477 | 518 |
| Operating Profit | 80 | 108 | 133 | 166 | 204 | 182 | 221 | 273 | 337 | 393 |
| OPM % | 32% | 37% | 39% | 44% | 44% | 40% | 40% | 40% | 41% | 43% |
| Other Income | 7 | 10 | 15 | 12 | 13 | 14 | 20.82 | 17 | 21 | 21 |
| Interest | 5 | 14 | 15 | 15 | 16 | 21 | 24 | 27 | 33 | 40 |
| Depreciation | 26 | 40 | 49 | 50 | 53 | 62 | 57 | 71 | 92 | 101 |
| PBT | 55 | 65 | 83 | 112 | 147 | 114 | 159 | 193 | 233 | 273 |
| Tax % | 37% | 29% | 25% | 24% | 25% | 25% | 25% | 26% | 26% | — |
| Net Profit | 35 | 46 | 63 | 85 | 111 | 85 | 120 | 144 | 173 | 204 |
| EPS (₹) | 3.44 | 4.50 | 6.13 | 8.29 | 10.76 | 8.29 | 11.61 | 14.01 | 16.81 | 19.79 |
| Div. Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% | 14% | 12% | — |
| Sales growth | — | 17 | 16 | 11 | 23 | −1 | 19 | 24 | 19 | 24 |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 157 | 203 | 270 | 354 | 458 | 535 | 647 | 789 | 947 | 1,047 |
| Borrowings | 33 | 146 | 161 | 141 | 183 | 248 | 259 | 320 | 423 | 509 |
| Other Liabilities | 39 | 53 | 46 | 41 | 62 | 61 | 66 | 155 | 127 | 167 |
| Total Liabilities | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 | 1,733 |
| Fixed Assets | 119 | 259 | 272 | 268 | 370 | 524 | 742 | 865 | 1,069 | 1,185 |
| CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 | 35 | 33 |
| Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 | 228 | 304 |
| Other Assets | 39 | 76 | 146 | 236 | 255 | 163 | 123 | 154 | 174 | 212 |
| Total Assets | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 | 1,733 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 62 | 91 | 106 | 130 | 158 | 165 | 183 | 224 | 271 |
| Investing | −98 | −90 | −31 | −130 | −123 | −110 | −141 | −182 | −174 |
| Financing | −8 | −7 | −30 | −49 | −31 | −42 | −45 | −52 | −69 |
| Net Cash Flow | −44 | −6 | 46 | −49 | 4 | 13 | −2 | −9 | 27 |
| Free Cash Flow | 32 | 31 | 69 | 98 | 37 | 40 | 99 | 132 | 91 |
| CFO/EBITDA | 103 | 101 | 98 | 97 | 97 | 105 | 98 | 97 | 96 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 11 | 9 | 6 | 8 | 8 | 11 | 8 | 9 |
| Inventory Days | 24 | 20 | 23 | 17 | 22 | 13 | 29 | 21 | 19 |
| Days Payable | 176 | 196 | 180 | 142 | 110 | 172 | 184 | 143 | 145 |
| Cash Conversion Cycle | −140 | −165 | −149 | −118 | −81 | −152 | −144 | −114 | −117 |
| Working Capital Days | −41 | −51 | −49 | −26 | −34 | −36 | −29 | −48 | −37 |
| ROCE % | — | 28% | 23% | 27% | 28% | 18% | 20% | 21% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vijaya Diagnostic Centre insights
63 extracted metrics across FY18–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Concall · Sep 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 25 Jun 2026
- 30 Apr 2025
- 8 Oct 2024
- 29 Feb 2024
- 29 Dec 2023
- General announcements 18 Nov 2026
Frequently Asked Questions about Vijaya Diagnostic Centre
What does Vijaya Diagnostic Centre Ltd do?
Where is Vijaya Diagnostic Centre Ltd (VIJAYA) listed?
Which sector does Vijaya Diagnostic Centre Ltd belong to?
What is the market capitalisation of Vijaya Diagnostic Centre Ltd?
What is the PE ratio of Vijaya Diagnostic Centre Ltd?
What is the 52-week high and low of Vijaya Diagnostic Centre Ltd?
Does Vijaya Diagnostic Centre Ltd pay dividends?
What is the Return on Equity (ROE) of Vijaya Diagnostic Centre Ltd?
Company Information
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIJAYA.md for Vijaya Diagnostic Centre Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.